Efficacy and Safety Evaluation of a Large Niacin Therapeutic Interchange Program

Chaffman, M; Webster, William; Winiecki, John T

doi:10.1345/aph.1r736

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Veterans who were on Niaspan (5321 subjects) were switched to Slo-Niacin and followed for 2 years. The results showed comparable safety/side effects and lipid benefits and Slo-Niacin had even greater lowering of TG [39]. A third NA product that uses a wax-matrix for its extended-release formulation is Endur-Acin (Endurance Products Inc).…”

Section: Choosing An Na Formulationmentioning

confidence: 99%

The Role of Niacin in the Management of Dyslipidemia†

Keenan¹

2019

Journal of Clinical Lipidology

View full text Add to dashboard Cite

Section: Choosing An Na Formulationmentioning

confidence: 99%

The Role of Niacin in the Management of Dyslipidemia†

Keenan¹

2019

Journal of Clinical Lipidology

View full text Add to dashboard Cite

“…However, this treatment was accompanied by unwanted side effects (reviewed in [5]), most prominently prostaglandin-dependent vasodilation in the skin (flushing) [6] and hepatotoxicity [7] (for review, see [8]), with the latter becoming negligible by applying niacin in a different formulation [9] (reviewed in [10]). Nevertheless, high niacin dosing can result in discomforting flushes [11], but niacin is still in use [12,13] and also marketed as a food supplement. Several studies showed protective effects of high NAD + levels in model systems as well as in humans under certain pathological conditions or in the context of the aging process, possibly due to preserving energy production in mitochondria [14][15][16][17][18][19][20].…”

Section: Nad + Supplementationmentioning

confidence: 99%

The NAD + precursor nicotinic acid improves genomic integrity in human peripheral blood mononuclear cells after X-irradiation

2017

View full text Add to dashboard Cite

NAD is an essential cofactor for enzymes catalyzing redox-reactions as well as an electron carrier in energy metabolism. Aside from this, NAD consuming enzymes like poly(ADP-ribose) polymerases and sirtuins are important regulators involved in chromatin-restructuring processes during repair and epigenetics/transcriptional adaption. In order to replenish cellular NAD levels after cleavage, synthesis starts from precursors such as nicotinamide, nicotinamide riboside or nicotinic acid to match the need for this essential molecule. In the present study, we investigated the impact of supplementation with nicotinic acid on resting and proliferating human mononuclear blood cells with a focus on DNA damage and repair processes. We observed that nicotinic acid supplementation increased NAD levels as well as DNA repair efficiency and enhanced genomic stability evaluated by micronucleus test after x-ray treatment. Interestingly, resting cells displayed lower basal levels of DNA breaks compared to proliferating cells, but break-induction rates were identical. Despite similar levels of p53 protein upregulation after irradiation, higher NAD concentrations led to reduced acetylation of this protein, suggesting enhanced SIRT1 activity. Our data reveal that even in normal primary human cells cellular NAD levels may be limiting under conditions of genotoxic stress and that boosting the NAD system with nicotinic acid can improve genomic stability.

show abstract

A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease

Rajabian

McCloskey

Jamialahmadi

et al. 2023

Reviews in the Neurosciences

View full text Add to dashboard Cite

There is a train of thought that lipid therapies may delay or limit the impact of neuronal loss and poor patient outcomes of neurodegenerative diseases (NDDs). A variety of medicines including lipid lowering modifiers (LLMs) are prescribed in NDDs. This paper summarizes the findings of clinical and observational trials including systematic reviews and meta-analyses relating to LLM use in NDDs published in the last 15 years thus providing an up-to-date evidence pool. Three databases were searched PubMed, CINAHL, and Web of Science using key terms relating to the review question. The findings confirm the benefit of LLMs in hyperlipidemic patients with or without cardiovascular risk factors due to their pleotropic effects. In NDDs LLMs are proposed to delay disease onset and slow the rate of progression. Clinical observations show that LLMs protect neurons from α-synuclein, tau, and Aβ toxicity, activation of inflammatory processes, and ultimately oxidative injury. Moreover, current meta-analyses and clinical trials indicated low rates of adverse events with LLMs when used as monotherapy. LLMs appear to have favorable safety and tolerability profiles with few patients stopping treatment due to severe adverse effects. Our collated evidence thus concludes that LLMs have a role in NDDs but further work is needed to understand the exact mechanism of action and reach more robust conclusions on where and when it is appropriate to use LLMs in NDDs in the clinic.

show abstract

Efficacy and Safety Evaluation of a Large Niacin Therapeutic Interchange Program

Cited by 4 publications

References 26 publications

The Role of Niacin in the Management of Dyslipidemia†

The Role of Niacin in the Management of Dyslipidemia†

The NAD + precursor nicotinic acid improves genomic integrity in human peripheral blood mononuclear cells after X-irradiation

A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease

Contact Info

Product

Resources

About